Health

Business Wire Australia and New Zealand

AVITA Medical Announces Hiring of Full U.S. Sales Team of Experienced Burn Professionals to Support National Launch of RECELL® System

16-Nov-2018 12:11 PM
Strong market response to the RECELL System approval in advance of U.S. launch with 32 burn centers actively reviewing the product or placing commercial orders   VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--AVITA Medical

Business Wire Australia and New Zealand

Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies

16-Nov-2018 9:16 AM
Boehringer Ingelheim Expands Biomarker-driven Oncology Programs Alliance Enhances Epizyme’s Leadership in Oncology Epigenetics CAMBRIDGE, Mass. and INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim and Epizyme

Business Wire Australia and New Zealand

SpinalCyte Announces Sustained 12-Month MRI Outcomes After CybroCell™ Injection

15-Nov-2018 11:07 AM
Data Shows Significant Improvement in Clinically Relevant Endpoints HOUSTON--(BUSINESS WIRE)--SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc nucleus using its universal donor product, CybroC

Business Wire Australia and New Zealand

ResMed Completes Acquisition of MatrixCare

15-Nov-2018 10:56 AM
SAN DIEGO--(BUSINESS WIRE)--ResMed (NYSE: RMD) (ASX: RMD), a leader in cloud-connected medical devices and out-of-hospital software-as-a-service (SaaS) business solutions, today announced it has completed its $750 million acquisition of Minne

Business Wire Australia and New Zealand

New Perth Children's Hospital Standardizes Care Team Communication With Vocera Technology

14-Nov-2018 11:37 AM
Clinicians can easily connect and collaborate on patient cases in real-time SAN JOSE, Calif.--(BUSINESS WIRE)--Vocera Communications, Inc. (NYSE:VCRA), a recognised leader in clinical communication and workflow solutions, today announced

Business Wire Australia and New Zealand

Gynesonics Technology to Be Featured in Presentations at 2018 American Association of Gynecologic Laparoscopists Global Congress

13-Nov-2018 8:58 AM
Impressive 12-Month Patient Outcomes from SONATA Pivotal IDE Trial Being Highlighted   REDWOOD CITY, Calif.--(BUSINESS WIRE)--Gynesonics, a women’s healthcare company focused on the development of advanced minimally invasive solu

Business Wire Australia and New Zealand

International Consensus Statement on Postoperative Anemia Management Recommends Noninvasive Hemoglobin Measurement Including Masimo SpHb®

12-Nov-2018 6:19 PM
Masimo Rad-67™ with SpHb® (Photo: Business Wire) NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today that a new consensus statement on postoperative anemia management was published in Anaesthesia b

Business Wire Australia and New Zealand

Prospective Study for NaturalVue Multifocal Demonstrates Decreased Refractive Error Change in Fast-Progressing Myopic Children

08-Nov-2018 12:20 PM
ATLANTA--(BUSINESS WIRE)--Thomas Aller, OD, FBCLA, an internationally recognized expert in nearsightedness in children, has presented updated findings from a prospective clinical trial of NaturalVue® (etafilcon A) 1 Day Multifocal Contact Lenses

Business Wire Australia and New Zealand

ResMed to Acquire MatrixCare, Expands Out-of-Hospital SaaS Portfolio into Long-Term Care Settings

06-Nov-2018 10:48 AM
Expands ResMed’s out-of-hospital software portfolio into skilled nursing and senior living verticals Enhances ResMed’s ability to improve patient transitions of care and provider efficiencies Purchase price $750 million, accretive

Business Wire Australia and New Zealand

Arima Genomics Completes Early Access Program and Launches the Arima-HiC Platform

06-Nov-2018 10:27 AM
Company introduces enhanced Arima-HiC product offering to drive greater insights for chromatin conformation and genome assembly studies SAN DIEGO--(BUSINESS WIRE)--Arima Genomics, Inc., a biotechnology company empowering research

Business Wire Australia and New Zealand

OptraSCAN® Unveils High-Speed, High-Throughput, High-Capacity and High-Content “Multi-Modality Digital Slide Scanner”

06-Nov-2018 10:14 AM
Fully equipped with Confocal, Epifluorescence and Brightfield imaging modalities   Introducing OptraSCAN's Multimodality Digital Slide Scanner (Graphic: Business Wire) SAN JOSE, Calif.--(BUSINESS WIRE)--OptraSCAN®, the lea

Business Wire Australia and New Zealand

Initial results from EMPRISE real-world evidence study shows empagliflozin was associated with reduced risk for hospitalisation for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease

06-Nov-2018 9:57 AM
  Empagliflozin was associated with a 44 percent reduction in relative risk of hospitalization for heart failure (HHF) compared with commonly used dipeptidyl peptidase-4 inhibitors1 Effect of empagliflozin on HHF was consistent

Business Wire Australia and New Zealand

U.S. Businessman Issues Global, Multimillion Dollar (USD) Challenge for Innovative Alzheimer’s Solutions

06-Nov-2018 9:24 AM
Oskar Fischer Prizes to be incubated by The University of Texas at San Antonio SAN ANTONIO--(BUSINESS WIRE)--To expand the understanding and explanation of Alzheimer’s disease, United States businessman James Truchard h

Business Wire Australia and New Zealand

Johnson & Johnson Innovation Announces Extension of JJIPO @ QUT in Collaboration with Queensland State Government to Further Boost Life-Science Innovation in Queensland

02-Nov-2018 10:34 AM
BRISBANE, Australia--(BUSINESS WIRE)--Johnson & Johnson Innovation announced the extension of the Johnson & Johnson Innovation Partnering Office at Queensland University of Technology (JJIPO @ QUT) for three years in collaboration wit

Business Wire Australia and New Zealand

Takeda to Present Data During 60th American Society of Hematology Annual Meeting on Wide Array of Treatment Needs for Blood Cancers

02-Nov-2018 9:38 AM
  – Results from Phase 3 Studies Including TOURMALINE-MM3 Trial of NINLARO™ (ixazomib) as Post- Autologous Stem Cell Transplant Maintenance Therapy and ECHELON-2 Trial of ADCETRIS® (brentuximab vedotin) in Frontline CD30-Pos

Business Wire Australia and New Zealand

Galderma, Nestlé Skin Health’s Medical Solutions Business, Announces Positive Results from Phase 2b Study of Nemolizumab in Patients with Moderate-to-Severe Atopic Dermatitis

31-Oct-2018 5:36 PM
  LAUSANNE, Switzerland--(BUSINESS WIRE)--Galderma, Nestlé Skin Health’s medical solutions business, today announced positive results from a Phase 2b dose-ranging study of nemolizumab in adult patients with moderate-to-severe atopic dermatiti

Business Wire Australia and New Zealand

Ferring Announces Retirement of Michel Pettigrew, President of the Executive Board and Chief Operating Officer

31-Oct-2018 5:22 PM
Michel Pettigrew, President of the Executive Board and Chief Operating Officer, will retire from his operational activities, effective December 31, 2018 Per Falk will be the next President of the Executive Committee and Chief Science Officer

Business Wire Australia and New Zealand

Takeda Reports Second Quarter FY2018 Results

31-Oct-2018 5:10 PM
Strong underlying growth driven by business momentum and strict OPEX discipline; Underlying Revenue +4.2%, Underlying Core Earnings +31.8%, Underlying Core EPS +32.7% Reported results impacted by large one-time gains in FY2017 and Shire

Business Wire Australia and New Zealand

Avita Medical First Quarter Fiscal 2019 Quarterly Cash Flow Report and Company Update

31-Oct-2018 4:27 PM
Recent Highlights FDA approval of RECELL® System for the treatment of acute thermal burns in adults Commencement of U.S. commercial sales and shipments Clinical results demonstrate patient benefits and cost savings in multiple conferen

Business Wire Australia and New Zealand

Janssen Presents Positive Long-Term Efficacy and Safety of SYMTUZA® (D/C/F/TAF) in Treatment-Naïve Adults with HIV-1

31-Oct-2018 8:38 AM
New Phase 3 AMBER study data continues to demonstrate high rates of virologic suppression at 96 weeks in ART-naïve adults with HIV-1 when treated with D/C/F/TAF1   GLASGOW, Scotland--(BUSINESS WIRE)--The Janssen Pharmaceu